Bill 2: An Act to Amend the Opioid Damages and Health Care Costs Recovery Act

This bill primarily affects companies in the pharmaceutical supply chain — opioid manufacturers, drug wholesalers, and marketing or consulting firms that advised on opioid products — who may now face legal action from both the New Brunswick provincial government and the federal government. Businesses in these industries, whether based in New Brunswick or elsewhere in Canada, now face a broader litigation exposure because the federal Crown gains its own independent right to sue, separate from the province's existing claims. The bill also makes it easier to pursue aggregate cost recovery without identifying individual patients, which lowers the evidentiary burden and makes large-scale lawsuits more viable. Smaller distributors and consultants, not just large manufacturers, are explicitly named as potential defendants.